TNTakashi Nakano

Takashi Nakano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takashi Nakano has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Respiratory Syncytial Virus Prefusion F IgG Antibodies in Japanese Mother–Infant Pairs Following Maternal Abrysvo Vaccination and in Infants Hospitalized with RSV Infection

    by Tomohiro Oishi, Takashi Nakano

    Background/Objectives: The approval of Abrysvo, a maternal bivalent respiratory syncytial virus (RSV) prefusion F (pre-F) vaccine, marked a major milestone in pediatric prophylaxis. However, real-world serological data on transplacental antibody transfer in Asian populations remains limited. This brief report evaluated serum RSV pre-F immunoglobulin G (IgG) geometric mean titers (GMTs) across three distinct Japanese cohorts. Methods: This single-center, comparative study analyzed neonates born to Abrysvo-vaccinated mothers (n = 12), neonates born to unvaccinated mothers (n = 40), and infants aged n = 18) using enzyme-linked immunosorbent assay (ELISA). Results: Neonates of vaccinated mothers exhibited significantly higher pre-F IgG GMTs (4.74; 95% CI: 4.30–5.18) than those of unvaccinated mothers (3.80; 95% CI: 3.50–4.14). Conversely, infants requiring hospitalization for RSV infection demonstrated critically low pre-F IgG GMTs (1.08; 95% CI: 0.65–2.15), revealing statistically significant differences across all three groups (p < 0.001). Conclusions: Maternal immunization with Abrysvo significantly enhances passive humoral immunity in Japanese neonates compared to natural background immunity. Given the severe antibody deficiency observed in hospitalized infants, expanding maternal vaccination coverage is a high-priority public health strategy to mitigate the pediatric RSV burden in the post-pandemic era.

  • Open Access

    Analysis of Macrolide Resistance in Bordetella pertussis Isolated from Japanese Children in 2025 Using Test Kit and Sequence Method

    by Tomohiro Oishi, Takashi Nakano

    Background: Bordetella pertussis causes pertussis, a respiratory infection with whooping cough. Despite a high vaccine coverage, pertussis resurged post-COVID-19 pandemic. Meanwhile, isolates resistant to macrolides—the first-line therapy—have increased in several countries, including Japan. Culturing B. pertussis and detecting resistance are difficult; reports remain limited in Japan. Methods: From March to August 2025, we collected nasopharyngeal samples from children aged 0–15 years with suspected pertussis at six Japanese clinics. Pediatricians obtained swabs and tested them using gene-amplification kits (e.g., BioFire® SpotFire® in four clinics, LAMP Pertussis Detection® in two clinics). B. pertussis was confirmed by PCR; isolates were sequenced to identify macrolide-resistant mutations. Results: Samples were taken from 54 children, the number of boys and girls was 34 and 20, and their median age was 12 years old. Among 54 B. pertussis isolates, 43/52 (82.7%) sequenced strains harbored the A2047G mutation associated with macrolide resistance. Resistance rates at each clinic varied from 40% to 96%. Conclusions: These findings indicate a post-pandemic rise in macrolide-resistant B. pertussis in Japan. Ongoing resistance surveillance is essential, and repurposing residual clinical samples after routine testing is useful given culture and detection challenges.


  • Open Access

    Long-Term Persistence of Anti-Poliovirus Antibody Titers After Two-Dose Booster Immunization with Conventional Inactivated Poliovirus Vaccine Among Japanese Adults: 10-Year Observational Study

    by Shinji Fukushima, Takashi Nakano, Minetaro Arita, Hiroyuki Shimizu, Atsuo Hamada

    Background/Objectives: Most Japanese adults received two doses of the oral polio vaccine (OPV) during childhood as part of the national immunization program. However, these two doses are considered suboptimal by global standards. The long-term persistence of anti-poliovirus antibodies after booster doses with the conventional inactivated poliovirus vaccine (cIPV) in Japanese adults remains unclear. This study was performed to evaluate long-term immunogenicity over a 10-year period following two cIPV booster vaccinations. Methods: Ten out of sixty-one adult participants in a short-term study were enrolled to assess the long-term immunogenicity of the booster vaccination. They underwent blood sampling at 3, 5, and 10 years after cIPV vaccination. Results: The results indicate that, even 10 years after the booster vaccination, antibodies against poliovirus types 1 and 2 remained at high levels, exceeding the detection limits of neutralization tests. However, some participants showed decreased antibody levels against poliovirus type 3. Conclusions: This study showed that cIPV boosters provided long-lasting protective immunity against poliovirus types 1 and 2 in adults who were vaccinated with OPV. These findings are valuable in assessing the need for IPV booster vaccinations in adults.


  • Open Access

    Evaluation of Virus Detection in Pediatric Patients Hospitalized with Respiratory Tract Infections Using Quantitative Multiplex PCR

    by Yuto Yasui, Tomohiro Oishi, Atsushi Kato, Satoko Ogita, Takahiro Eitoku, Hideo Enoki, Takashi Nakano

    Respiratory tract infections (RTIs) are common in children. Viruses are known to be related to most pediatric infections. However, some pediatric cases of RTI have been found to be associated with multiple viruses. In this study, we collected samples from the nasopharynx of all pediatric patients admitted to our hospital with RTI between April 2022 and March 2023 and performed multiple quantitative real-time PCRs. Out of 77 patients involved, 67 (87.0%) tested positive for some or the other virus. Rhinovirus was the most detected, followed by the RS virus and parainfluenza virus type 3. Among the patients, 18 (26.9%) had multiple viral infections and 14 had complications associated with obstructive respiratory diseases, including bronchial asthma, acute bronchiolitis, and asthmatic bronchitis. Furthermore, some cases were found to have both the main and non-main viruses. Multiple viruses were detected in approximately one-fourth of the children with RTIs; complications associated with obstructive respiratory diseases were considered to be the main factors.

  • Open Access

    Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naïve Japanese adults: A phase 1 randomized dose-escalation trial

    by Dorota Borys, Ronald Smulders, Miwa Haranaka, Takashi Nakano, Gurunadh R. Chichili, Masaki Ebara, Atsuki Hashimoto, Mioko Iwahana, Yuki Oizumi, Jasdeep Nanra, et al.


  • Open Access

    Maximum Diameter of Ileocecal Lymph Nodes Measured Using Abdominal Ultrasonography Allows for the Discrimination of Yersinia pseudotuberculosis Infection from Kawasaki Disease

    by Atsushi Kato, Ippei Miyata, Yoshitaka Nakamura, Takaaki Tanaka, Yutaka Ma Koguchi, Tomohiro Oishi, Takashi Nakano, Kazunobu Ouchi

    Background: This study aimed to determine whether the maximum diameter of ileocecal lymph nodes measured using abdominal ultrasonography is useful for differentiating Yersinia pseudotuberculosis infection from Kawasaki disease in the acute phase. The optimal maximum diameter cutoff of the ileocecal lymph nodes was also explored to optimize differentiation between these 2 diseases. Methods: We included pediatric patients Y. pseudotuberculosis infection. Results: Of the 122 patients included in the analysis, 17 were confirmed to have Y. pseudotuberculosis infection and 105 were not. The age (in months), white blood cell count, C-reactive protein level, prediction score (risk score) for nonresponse to intravenous immunoglobulin, and number of intravenous immunoglobulin doses did not differ significantly between the Y. pseudotuberculosis-positive and -negative groups. The maximum diameter of ileocecal lymph nodes was 6.0 (5.5–9.5) mm in the Y. pseudotuberculosis-positive group and 3.0 (2.5–3.8) mm in the Y. pseudotuberculosis-negative group (numbers presented as median, interquartile range), with a significantly larger diameter in the Y. pseudotuberculosis-positive group (P < 0.01, Mann–Whitney U test), suggesting potency of ultrasonography. Conclusion: In patients meeting the diagnostic criteria for Kawasaki disease, the possibility of Y. pseudotuberculosis infection is significantly higher if the maximum ileocecal lymph node diameter ≥5.1 mm. Its sensitivity and specificity being 100%, and 89.5%, respectively.


  • Open Access

    Evaluation of Neutralizing Antibodies on Respiratory Syncytial Virus in Japanese Mother-Infant Pairs after COVID-19 Pandemic

    by Tomohiro Oishi, Daisuke Yoshioka, Sachie Ono, Yuto Yasui, Atsushi Kato, Satoko Ogita, Tomoaki Tokutomi, Mazumi Miura, Takahiro Eitoku, Hideo Enoki, et al.

    Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infection in young children globally. Following the COVID-19 pandemic, RSV infections have become more prevalent. Consequently, a new vaccine targeting RSV infections in pregnant women has been introduced worldwide. To estimate the effectiveness of this new vaccine for pregnant women, we investigated neutralizing antibodies against RSV in samples taken from 51 mothers and their babies. The prevalence rate of neonatal antibodies, defined as a titer of ≥16, was 39.2%. We found no significant differences in neonatal neutralizing antibodies based on factors, such as sex, gestational age at birth, birth weight, presence of siblings, neonatal problem, and usage of palivizumab. Neonatal neutralizing antibodies were equal to or higher than those of their mother. A new RSV vaccine targeting all pregnant women is promising, as approximately 60% of neonates had low antibody titers against RSV. However, predicting low antibody titer against RSV remains challenging. Moreover, our findings indicate efficient transmission of RSV antibodies from babies to their mothers.

  • Open Access

    Analysis of Cell Immunity for Children Infected with SARS-CoV-2 and Those Vaccinated against SARS-CoV-2 Using T-SPOT®.COVID

    by Tomohiro Oishi, Yuto Yasui, Atsushi Kato, Satoko Ogita, Takahiro Eitoku, Hideo Enoki, Takashi Nakano

    Cellular immunity is critical for the regulation of viral diseases, including coronavirus disease 2019 (COVID-19), and is generally considered immature in childhood. However, the details of cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among children are unclear. We assessed cellular immunity in eight children post-vaccination against SARS-CoV-2 and 11 children after SARS-CoV-2 infection using the T-SPOT®.COVID assay for the spike (S) and nucleocapsid (N) proteins. In the vaccinated group, the T-SPOT®.COVID assay for the S protein yielded positive results in seven children. In the post-infection group, the assay for the N protein was positive for 5 of 11 children, with 3 of these 5 children requiring hospitalization, including 2 who needed mechanical ventilation. The T-SPOT®.COVID assay is thus valuable for assessing cellular immunity against SARS-CoV-2, and most children infected with SARS-CoV-2 may not develop such immunity unless the disease severity is significant.


  • Open Access

    Analysis of Cell Immunity for Children Infected with COVID-19 and Those Vaccinated against COVID-19 Using T-SPOT®.COVID

    by Tomohiro Oishi, Yuto Yasui, Atsushi Kato, Satoko Ogita, Takahiro Eitoku, Hideo Enoki, Takashi Nakano

    To elucidate the cellular immune response to coronavirus disease (COVID-19) among children, we assessed cellular immunity in 8 children post-vaccination for COVID-19 and 11 children after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, using the T-SPOT®.COVID assay for both the spike (S) and nucleocapsid (N) proteins. In the vaccinated group, the T-SPOT®.COVID assay for the S protein yielded positive results in all eight children. In contrast, in the post-infection group, the assay for the N protein was positive in 5 of 11 children, with 3 of these 5 children requiring hospital admission, including 2 who needed mechanical ventilation. Therefore, the T-SPOT®.COVID assay is valuable for assessing cellular immunity against COVID-19, and most children infected with COVID-19 may not develop such immunity unless the disease severity is significant.